Do cetuximab, oxaliplatin, and 5-fluorouracil cause hearing loss or ototoxicity?

Ototoxicity Risk of Cetuximab, Oxaliplatin, and 5-Fluorouracil

Oxaliplatin very rarely causes hearing loss, cetuximab does not cause ototoxicity, and 5-fluorouracil does not affect hearing when given systemically. Among these three agents, only oxaliplatin poses any documented risk to hearing, and this risk is minimal compared to other platinum agents.

Individual Agent Risk Profile

Oxaliplatin - Minimal but Documented Risk

According to the 2020 ESMO-EONS-EANO guidelines, oxaliplatin very rarely causes ototoxicity 1. This represents the highest quality guideline evidence available and directly addresses your question.

However, emerging research challenges this traditional view:

• Recent preclinical data (2026) demonstrates that oxaliplatin can cause "hidden" cochlear synaptopathy - neural damage without threshold changes 2
• This manifests as loss of ribbon synapses, reduced spiral ganglion cells, and impaired medial olivocochlear reflex function despite normal hearing thresholds
• Clinical case reports document rare instances of sudden sensorineural hearing loss with oxaliplatin 3, 4, 5
• The incidence appears to be less than 1% of patients 5

Clinical implication: While guidelines state oxaliplatin "very rarely" causes ototoxicity, this may underestimate subclinical neural damage that standard audiometry cannot detect.

Cetuximab - No Ototoxic Risk

The FDA label for cetuximab (ERBITUX) does not list hearing loss or ototoxicity among adverse reactions in any clinical trial 6. In the EXTREME trial combining cetuximab with platinum-based therapy and fluorouracil, no hearing-related adverse events were attributed to cetuximab specifically.

5-Fluorouracil - No Systemic Ototoxic Risk

5-Fluorouracil administered systemically does not cause ototoxicity. The only evidence of potential hearing effects comes from topical middle ear application in animal models 7, which is not relevant to systemic chemotherapy administration.

Risk Stratification for Your Regimen

For patients receiving cetuximab + oxaliplatin + 5-FU:

• Primary concern: Oxaliplatin's rare ototoxic potential
• No additive risk: Neither cetuximab nor 5-FU contribute to hearing loss
• Overall risk: Very low (<1% for clinically apparent hearing loss)

Monitoring Recommendations

Based on guideline evidence, routine audiometric monitoring is NOT required for this regimen 1. The 2019 International Late Effects guideline explicitly states "unknown risk after oxaliplatin" and does not recommend surveillance 8.

However, implement these practical measures:

1. Pre-treatment counseling: Inform patients that hearing loss is very rare but possible
2. Symptom surveillance: Instruct patients to report immediately:
   • Sudden hearing changes
   • Tinnitus (ringing in ears)
   • Difficulty understanding speech, especially in noise
3. Clinical vigilance: If symptoms develop, obtain formal audiometry and consider dose modification or discontinuation
4. Avoid co-administration of other ototoxic agents (aminoglycosides, loop diuretics) when possible 1

Key Clinical Pitfalls

• Do not confuse oxaliplatin with cisplatin: Cisplatin causes ototoxicity in 20-75% of patients 1; oxaliplatin's risk is orders of magnitude lower
• Standard audiometry may miss early damage: The 2026 preclinical data suggests oxaliplatin may cause neural damage without threshold changes 2, but clinical tests for this are not yet standard of care
• Age matters: Younger patients may be at higher risk if ototoxicity occurs 8

Bottom Line

You can reassure patients that this regimen poses minimal risk to hearing. Oxaliplatin carries a very rare (<1%) risk of hearing loss, while cetuximab and 5-FU do not affect hearing. Routine audiometric monitoring is not indicated, but maintain clinical vigilance for patient-reported symptoms. If hearing changes occur, obtain formal audiological evaluation and consider treatment modification.